Relatlimab, Nivolumab Improve Progression-Free Survival in Metastatic Melanoma
The FDA granted priority review to the combination of relatlimab and nivolumab in September 2021 based on the results of this study.The combination of relatlimab...
The FDA granted priority review to the combination of relatlimab and nivolumab in September 2021 based on the results of this study.The combination of relatlimab...
